Drug intelligence / Profile preview

HX011

Development stage: Unknown
Lead developer: Wuhan Houxian Biomedical
Modality: Oncolytic Viruses → Oncolytic Therapeutics
Administration: Intratumoral

Overview

HX011 is an investigational oncolytic virus therapy developed by Wuhan Houxian Biotechnology for the treatment of advanced solid tumors. It is based on an engineered Herpes Simplex Virus type 1 (oHSV-1) platform designed to selectively replicate within and lyse malignant cells while stimulating a systemic anti-tumor immune response. Administered via intratumoral injection, HX011 aims to turn "cold" tumors "hot" by increasing immune cell infiltration and promoting the release of tumor-associated antigens. The therapy is currently being evaluated in a Phase 1 clinical trial (CTR20262433) in China to assess its safety, tolerability, and preliminary antitumor activity in patients with advanced malignancies.

Beyond the preview

Go deeper on HX011.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HX011.

Explore the full profile